Abstract: In a method for a cooktop, in particular for producing and/or operating the cooktop, which has at least one variable cooking surface, the cooking surface is partitioned in an operating mode along a partitioning direction into a plurality of heating zones to which at least one heating parameter is assigned in each case in a location-dependent manner in order to heat a cooking utensil that is deposited on the heating zone. In order to ensure flexible production and/or flexible operation of the cooktop, during partitioning of the cooking surface into the heating zones in at least one peripheral region of the cooking surface, at least one cooking utensil characteristic is taken into account.

Abstract: The present disclosure relates to methods of treating or preventing various diseases or disorders, such as cardiac fibrosis, aortic fibrosis, pulmonary fibrosis, renal fibrosis, dermal fibrosis, and chronic kidney diseases, using cannabidiol derivatives or compositions thereof.

Abstract: It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is: and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells. As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.

Abstract: It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is: and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells. As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.

Abstract: A novel biomass derived catalyst doped porous carbon material and efficient methods to produce it. The doped porous carbon material can be used as a host to generate several materials with a higher performance than exhibited by previous materials. The host material performance enhancement is due to ability to control the amount of doping material, material structure, surface property, and pore size, as well as a high surface area and large pore volume allowing for high sulfur loading. In addition, the hierarchical structure of the porous composites allows an increased in energy density and long cycle life.

Abstract: It is disclosed a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a linear alkyl group of 3 or 5 carbon atoms, and R2 is: and a pharmaceutical composition comprising the same, for use in the treatment of a disease whose treatment benefits from inhibiting or reducing Notch1 expression levels in cells, and/or benefits from inhibiting or reducing Notch1 levels in cells, and/or benefits from inhibiting or reducing Notch1 signaling dependent proteins levels in cells. As a consequence, present invention also relates to said compound of formula (I), and to the pharmaceutical composition comprising the same, for use in suppressing cancer stem cells, as well as, for use in reducing solid tumor development, metastasis or chemo/radio-resistance, promoted by cancer stem cells.

Abstract: A transformer assembly includes: a first switching apparatus configured to be electrically connected to a first segment of a transformer loop; a second switching apparatus configured to be electrically connected to a second segment of the transformer loop; and a transformer including: a first coil electrically connected to the first switching apparatus and the second switching apparatus; and a second coil electrically connected to an output configured to electrically connect to a load.

Abstract: Compositions, comprising the cannabidiol derivatives of Formula (I) in pharmaceutical formulations displaying increased bioavailability and solubility are described. Cannabidiol derivatives of Formula (I) and compositions comprising the same for use in the treatment of various conditions, and diseases, including diseases associated with demyelination.

Abstract: A compound of formula I or a pharmaceutical salt thereof of formula II, as well as a process to obtain said compound and a process to obtain said salt. Additionally, disclosed is the use of said compound of formula I or said pharmaceutical salt thereof of formula II as a medicament, in particular as a peroxisome proliferator-activated receptor gamma (PPAR?) agonist, for use in the treatment or prevention of a disease responsive to PPAR? agonists. Also disclosed is a pharmaceutical composition comprising said compound or said salt, as well as a method of treating or preventing a disease with said compound of formula I or said salt thereof of formula II, or with a composition comprising said compound or said salt.

Abstract: Described are assays, associated assay kits, and associated methods for diagnosing an infection in a subject. The assay includes a first binding molecule that specifically binds an inflammatory marker (i.e., neutrophil gelatinase-associated lipocalin (NGAL) homodimer) in a sample taken from the subject, and a second binding molecule that binds a marker indicative of the presence of a pathogen in the sample. The assay and methods are for the diagnosis of peritonitis in peritoneal dialysis patients.

Abstract: Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF-1? and HIF-2? levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types and induce collagen contraction. Said cannabidiol quinol derivatives of Formula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia-reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.

Abstract: Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF-1? and HIF-2? levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types and induce collagen contraction. Said cannabidiol quinol derivatives of Formula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia-reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.

Abstract: Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R?—C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1? and HIF-2? proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-?B inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors.

Abstract: Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF-1? and HIF-2? levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types and induce collagen contraction. Said cannabidiol quinol derivatives of Formula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia-reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.

Abstract: Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R?—C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1? and HIF-2? proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-?B inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors.

Abstract: A method for making a segmentation in the sorted sequence of data (100), that comprises arranging a sequential stream of sorted input data (10), where the data are arranged in matrices (frames), in this case by way of a preferred example as a sequence of images for image analysis (20), and that delivers a sequential stream of sorted output data (30), where the sorted output data are arranged in sorted matrices.

Abstract: A method for making a segmentation in the sorted sequence of data (100), that comprises arranging a sequential stream of sorted input data (10), where the data are arranged in matrices (frames), in this case by way of a preferred example as a sequence of images for image analysis (20), and that delivers a sequential stream of sorted output data (30), where the sorted output data are arranged in sorted matrices.

Abstract: The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.

Abstract: The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.

Abstract: The present invention relates to a thermally-resistant woven fabric and/or multiple ply fabric sheet for use as single or outer layer of protective garments, of the type comprising an inside fabric layer and an outside fabric layer joined together by an array of connecting lines. The woven fabric and/or multiple ply fabric sheet comprise yarns, wherein said yarn comprises i) meta-aramid ii) from about 5 to 10 weight % of polyamide and iii) at least 2 weight % of antistatic fibers, the weight % being based on the total weight of the yarn.